Bharat Parenterals Ltd
Bharat Parenterals Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹116.00 Cr, PAT ₹0.86 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Bharat Parenterals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Consolidated Q1 FY26 vs Q1 FY25: - EBITDA: ₹13.78 crore, +206.9% YoY - EBITDA Margin: 11.9% (up from 4.9%) - PAT: -₹0.86 crore, improved from -₹8.85 crore (90.3% improvement) - PAT Margin: -
From Bharat Parenterals Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26).
- Total Operating Revenue (Consolidated): ₹117.06 crore, up 23.2% YoY from ₹95.05 crore in Q1 FY 2025 (Page 26).
- Standalone Revenue from Operations: ₹94.37 crore, up 2.51% YoY from ₹92.06 crore in Q1 FY 2025 (Page 24).
- Standalone Total Operating Revenue: ₹95.84 crore, essentially flat YoY (-0.13%) compared to ₹95.96 crore in Q1 FY 2025 (Page 24).
- FY26 Revenue Outlook: BPL projects standalone revenue growth of 12–14% supported by strong order book and capacity utilization (Page 25).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Bharat Parenterals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 10).
- Varenyam Bio Lifesciences: Capex till date ~₹30 crore; manufacturing facility under construction; targeted operational readiness by FY27 (Page 10).
- BPL (Standalone): No direct capex mentioned for new plants, but FY25 capex was ₹14+ crore (Page 10).
- Expansion planned:
- Innoxel’s commercial CMO supplies expected to commence Q1 FY27 after EU-GMP inspection in FY26 (Page 25).
- Varenyam Healthcare expects to leverage BPL’s manufacturing for volume and segment expansion (Page 11).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Bharat Parenterals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net loss ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY26 investor presentation — and how it ranks a
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key investor presentation takeaways from Influx Healthtech Ltd'
- Shree Ganesh Remedies Ltd (Q1 FY26)
Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it
- Anuh Pharma Ltd (Q1 FY26)
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma
Frequently Asked Questions
What were Bharat Parenterals Ltd Q1 FY26 results?
Q1 FY 2026 Revenue from Operations (Consolidated): ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Consolidated Q1 FY26 vs Q1 FY25: - EBITDA: ₹13.78 crore, +206.9% YoY - EBITDA Margin: 11.9% (up from 4.9%) - PAT: -₹0.86 crore, improved from -₹8.85 crore (90.3% improvement) - PAT Margin: -
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,040 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Innoxel Lifesciences: Capex ~₹250 crore; facility fully constructed, USFDA inspected, undergoing product validation (Page 10).
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.